keyword
MENU ▼
Read by QxMD icon Read
search

Biomarker lymphoma

keyword
https://www.readbyqxmd.com/read/29228840/investigational-pd-1-inhibitors-in-hl-and-nhl-and-biomarkers-for-predictors-of-response-and-outcome
#1
Andres Chang, Danielle Schlafer, Christopher R Flowers, Pamela B Allen
Inhibitors against the PD-1/PD-L1 pathway are revolutionizing the treatment and management of malignancies. Areas covered: We summarize our current understanding of the function of PD-1, its role in immune evasion, the clinical data available that support the use of PD-1 antagonist in Hodgkin and non-Hodgkin lymphomas, and potential predictors of response. Expert opinion: We anticipate that in the next 10 years, agents that modulate the immune system such as PD-1 antagonists will be increasingly used in favor over traditional cytotoxic chemotherapeutic agents...
December 12, 2017: Expert Opinion on Investigational Drugs
https://www.readbyqxmd.com/read/29228708/blood-biomarkers-in-adults-with-lymph-node-enlargement-contribute-to-diagnostic-significance-of-malignancy
#2
Shanshan Ma, Junbin Guo, Danlei Lu, Lixia Zhu, Meng Zhou, De Zhou, Li Li, Jingjing Zhu, Xiudi Yang, Yanlong Zheng, Xiujin Ye, Wanzhuo Xie
Lymph node enlargement is a common presentation and has a possibility of malignancy like lymphoma that requires early diagnosis. This study aims to analyze the clinical characteristics of these patients and finds out useful predictors of malignant diseases. We retrospectively investigated 81 patients with lymph node enlargement between July 2, 2014 and May 17, 2016. The characteristics and laboratory findings were evaluated combining with the final diagnosis. The diagnoses were malignancy in 51 patients and benign lymphadenopathy in 30 patients...
November 17, 2017: Oncotarget
https://www.readbyqxmd.com/read/29226797/axicabtagene-ciloleucel-car-t-cell-therapy-in-refractory-large-b-cell-lymphoma
#3
Sattva S Neelapu, Frederick L Locke, Nancy L Bartlett, Lazaros J Lekakis, David B Miklos, Caron A Jacobson, Ira Braunschweig, Olalekan O Oluwole, Tanya Siddiqi, Yi Lin, John M Timmerman, Patrick J Stiff, Jonathan W Friedberg, Ian W Flinn, Andre Goy, Brian T Hill, Mitchell R Smith, Abhinav Deol, Umar Farooq, Peter McSweeney, Javier Munoz, Irit Avivi, Januario E Castro, Jason R Westin, Julio C Chavez, Armin Ghobadi, Krishna V Komanduri, Ronald Levy, Eric D Jacobsen, Thomas E Witzig, Patrick Reagan, Adrian Bot, John Rossi, Lynn Navale, Yizhou Jiang, Jeff Aycock, Meg Elias, David Chang, Jeff Wiezorek, William Y Go
Background In a phase 1 trial, axicabtagene ciloleucel (axi-cel), an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, showed efficacy in patients with refractory large B-cell lymphoma after the failure of conventional therapy. Methods In this multicenter, phase 2 trial, we enrolled 111 patients with diffuse large B-cell lymphoma, primary mediastinal B-cell lymphoma, or transformed follicular lymphoma who had refractory disease despite undergoing recommended prior therapy. Patients received a target dose of 2×106 anti-CD19 CAR T cells per kilogram of body weight after receiving a conditioning regimen of low-dose cyclophosphamide and fludarabine...
December 10, 2017: New England Journal of Medicine
https://www.readbyqxmd.com/read/29226652/a-pooled-analysis-of-the-clinical-utilities-of-long-non-coding-rna-based-molecular-signature-for-diffuse-large-b-cell-lymphoma
#4
Pei Xu, Xiaoli Chen, Panke Su
BACKGROUND: Long non-coding RNAs (lncRNAs) have been highlighted as promising biomarkers for several types of malignancies. The current meta-analysis sought to investigate the clinical value of lncRNA-based molecular signatures as biomarkers for diagnosis, subtype classification, and prognosis in diffuse large B cell lymphoma (DLBCL). METHODS: A systematic search of the online databases was carried out and data were retrieved by pairs of independent reviewers. Effect sizes of the diagnostic parameters were combined using a quantitative meta-analysis...
November 1, 2017: Clinical Laboratory
https://www.readbyqxmd.com/read/29222307/secondary-cns-relapse-in-diffuse-large-b-cell-lymphoma-defining-high-risk-patients-and-optimization-of-prophylaxis-strategies
#5
REVIEW
Kerry J Savage
Despite improvement in survival in diffuse large B-cell lymphoma (DLBCL) with the introduction of rituximab, central nervous system (CNS) relapse continues to represent a clinical challenge. A number of studies have evaluated clinical risk factors in an attempt to identify high-risk patients to direct CNS staging investigations and consider prophylaxis strategies. The CNS International Prognostic Index is a robust and reproducible risk model that can identity patients at high risk of CNS relapse, but its specificity remains limited...
December 8, 2017: Hematology—the Education Program of the American Society of Hematology
https://www.readbyqxmd.com/read/29222281/improved-biological-insight-and-influence-on-management-in-indolent-lymphoma-talk-3-update-on-nodal-and-splenic-marginal-zone-lymphoma
#6
REVIEW
Catherine Thieblemont
Splenic marginal zone lymphoma (SMZL) and nodal marginal zone lymphoma (NMZL) are rare indolent chronic B-cell lymphomas. Prognosis is typically good with median survival around 10-15 years. Management is generally based on the presence of symptoms or high tumor burden. There are no standard treatments for these 2 entities, and therapeutic strategies are rapidly evolving. Clinical developments for these 2 entities are oriented by genomic studies, with largely overlapping mutational profiles involving the NOTCH, B-cell receptor (BcR) and nuclear factor κB (NF-κB) signaling, chromatin remodeling, and the cytoskeleton...
December 8, 2017: Hematology—the Education Program of the American Society of Hematology
https://www.readbyqxmd.com/read/29222279/follicular-lymphoma-are-we-ready-for-a-risk-adapted-approach
#7
REVIEW
Brad S Kahl
Follicular lymphoma is the most common indolent non-Hodgkin lymphoma in the Western hemisphere. The natural history of FL appears to have been favorably impacted by the introduction of rituximab after randomized clinical trials demonstrated that the addition of rituximab to standard chemotherapy induction has improved the overall survival. Yet, the disease is biologically and clinically heterogeneous with wide variations in outcomes for individual patients. The ability to accurately risk-stratify patients and then tailor therapy to the individual is an area of ongoing research...
December 8, 2017: Hematology—the Education Program of the American Society of Hematology
https://www.readbyqxmd.com/read/29209918/molecular-classification-and-precision-therapy-of-cancer-immune-checkpoint-inhibitors
#8
Yingyan Yu
On May 23, 2017, the US Food and Drug Administration (FDA) approved a treatment for cancer patients with positive microsatellite instability-high (MSI-H) markers or mismatch repair deficient (dMMR) markers. This approach is the first approved tumor treatment using a common biomarker rather than specified tumor locations in the body. FDA previously approved Keytruda for treatment of several types of malignancies, such as metastatic melanoma, metastatic non-small-cell lung cancer, recurrent or metastatic head and neck cancer, refractory Hodgkin lymphoma, and urothelial carcinoma, all of which carry positive programmed death-1/programmed death-ligand 1 biomarkers...
December 5, 2017: Frontiers of Medicine
https://www.readbyqxmd.com/read/29202805/clinical-significance-of-pcdh10-promoter-methylation-in-diffuse-large-b-cell-lymphoma
#9
Wenting Huang, Xuemin Xue, Ling Shan, Tian Qiu, Lei Guo, Jianming Ying, Ning Lu
BACKGROUND: PCDH10, one of the non-clustered protocadherins, is identified as a tumor suppressor gene in many tumors. Recently, promoter methylation of PCDH10 was found in diffuse large B-cell lymphoma (DLBCL) but not in normal lymph nodes, suggesting that its epigenetic aberrance is essential to the lymphomagenesis. However, there are few studies on the clinicopathological relevance and prognostic significance of PCDH10 methylation status in DLBCL. METHODS: One hundred-seven cases of DLBCL between Jan 2009 and Jul 2010 were selected to extract genomic DNA and perform bisulfite modification...
December 4, 2017: BMC Cancer
https://www.readbyqxmd.com/read/29202455/a-simple-clinically-relevant-therapeutic-vaccine-shows-long-term-protection-in-an-aggressive-delayed-treatment-b-lymphoma-model
#10
Pallab Pradhan, Jardin Leleux, Jiaying Liu, Krishnendu Roy
Despite initial remission after successful treatments, B lymphoma patients often encounter relapses and resistance causing high mortality. Thus, there is a need to develop therapies that prevent relapse by providing long-term protection and, ultimately, lead to functional cure. In this study, our goal was to develop a simple, clinically relevant, and easily translatable therapeutic vaccine that provides durable immune protection against aggressive B cell lymphoma and identify critical immune biomarkers that are predictive of long-term survival...
November 16, 2017: JCI Insight
https://www.readbyqxmd.com/read/29199689/clinical-profile-of-nonsmall-cell-lung-carcinoma-patients-treated-in-a-single-unit-at-a-tertiary-cancer-care-center
#11
D C Doval, R Sinha, U Batra, K D Choudhury, S Azam, A Mehta
BACKGROUND: Recent advances and understanding in the field of lung cancer and advent of newer treatments have shown a significant improvement in survival in the patients. The present study was conducted to analyze the clinical profile of nonsmall cell lung cancer (NSCLC) patients treated in a single unit at a tertiary cancer care center. MATERIALS AND METHODS: In this retrospective analysis, 322 consecutive NSCLC patients from the year 2011 to 2012 treated in a single unit were included in the study...
January 2017: Indian Journal of Cancer
https://www.readbyqxmd.com/read/29199055/bone-marrow-involvement-in-malignant-lymphoma-evaluation-of-quantitative-pet-and-mri-biomarkers
#12
Ulrika Asenbaum, Richard Nolz, Georgios Karanikas, Julia Furtner, Ramona Woitek, Ingrid Simonitsch-Klupp, Markus Raderer, Marius E Mayerhoefer
RATIONALE AND OBJECTIVES: This study aimed to determine the diagnostic utility of standardized uptake values (SUV) and apparent diffusion coefficients (ADC) for assessment of focal and diffuse bone marrow involvement in patients with malignant lymphoma. MATERIALS AND METHODS: Sixty treatment-naive patients (28 males; mean age 51.2 ± 16.7 years) with histologically proven lymphoma, who underwent fludeoxyglucose (18F) positron emission tomography-computed tomography ([F18]-FDG-PET/CT) and whole-body diffusion-weighted imaging (WB-DWI) within 7 days, and also routine bone marrow biopsy, were included in this institutional review board-approved, retrospective study...
November 30, 2017: Academic Radiology
https://www.readbyqxmd.com/read/29195620/pet-ct-in-lymphoma-current-overview-and-future-directions
#13
REVIEW
Bruce D Cheson
Over the past several decades, PET has emerged as critical to accurate staging and restaging of lymphomas. Nonetheless, a number of critical issues regarding its optimal use remain. Whereas risk-adapted strategies appear to improve the outcome of patients with Hodgkin lymphoma, results are less convincing in non-Hodgkin lymphoma. Assessment of metabolic tumor volume before treatment may permit novel induction strategies. New drugs that may induce an immune response may result in a false-positive FDG/PET scan, mandating modifications of current criteria to consider tumor flare reactions...
January 2018: Seminars in Nuclear Medicine
https://www.readbyqxmd.com/read/29184678/liquid-biopsy-for-monitoring-anaplastic-lymphoma-kinase-inhibitors-in-non-small-cell-lung-cancer-two-cases-compared
#14
REVIEW
Mariangela Manicone, Maria Chiara Scaini, Maria Grazia Rodriquenz, Antonella Facchinetti, Alfredo Tartarone, Michele Aieta, Rita Zamarchi, Elisabetta Rossi
Three to seven percent of non-small cell lung cancer (NSCLC) patients show anaplastic lymphoma kinase (ALK)-translocation and could be treated with ALK-inhibitors. However, under crizotinib, a first-generation ALK-inhibitor, patients develop drug resistance after a median of 12 months. To overcome crizotinib resistance, several next-generation ALK inhibitors have been developed. In NSCLC, liquid biopsy allowed important improvements in the detection of the epidermal growth factor receptor (EGFR) mutation. The ability of liquid biopsy to detect oncogenic gene/protein fusions is a newly investigated field, and is not routinely applied yet...
October 2017: Journal of Thoracic Disease
https://www.readbyqxmd.com/read/29184673/critical-issues-in-the-clinical-application-of-liquid-biopsy-in-non-small-cell-lung-cancer
#15
REVIEW
Mariangela Manicone, Cristina Poggiana, Antonella Facchinetti, Rita Zamarchi
Current therapeutic options for non-small cell lung cancer (NSCLC) patients are chemotherapy and targeted therapy directed mainly against epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) rearrangements. Targeted therapy relies on the availability of tumor biopsies for molecular profiling at diagnosis and to longitudinally monitor treatment response and resistance development. Unfortunately, tumor biopsy might be invasive, recover poor material of suboptimal quality, and cause sample bias due to tumor heterogeneity...
October 2017: Journal of Thoracic Disease
https://www.readbyqxmd.com/read/29160924/accelerated-untargeted-metabolomics-analysis-of-cutaneous-t-cell-lymphoma-reveal-metabolic-shifts-in-plasma-and-tumor-adjacent-skins-of-xenograft-mice
#16
Yunchen Le, Xiaoyan Shen, Hongyan Kang, Qizheng Wang, Kejia Li, Jie Zheng, Yunqiu Yu
Cutaneous T-cell lymphoma (CTCL) is a heterogeneous group of skin-homing T-cell neoplasms. Clinical management is stage based but diagnosis and prognosis could be extremely challenging. The presented study aims to explore the metabolic profiling of CTCL by an accelerated untargeted metabolomics data analysis tool "mummichog" to facilitate the discoveries of potential biomarkers for clinical early-stage diagnosis, prognosis and treatments in CTCL. Ultra-high-performance liquid chromatography-quadrupole time-of-flight (UHPLC-QTOF) based untargeted metabolomics were conducted on the skin and plasma of CTCL mice...
November 21, 2017: Journal of Mass Spectrometry: JMS
https://www.readbyqxmd.com/read/29158470/comparative-oncology-evaluation-of-intravenous-recombinant-oncolytic-vesicular-stomatitis-virus-therapy-in-spontaneous-canine-cancer
#17
Shruthi Naik, Gina D Galyon, Nathan J Jenks, Michael B Steele, Amber C Miller, Sara D Allstadt, Lukkana Suksanpaisan, Kah Whye Peng, Mark J Federspiel, Stephen J Russell, Amy K LeBlanc
Clinical translation of intravenous therapies to treat disseminated or metastatic cancer is imperative. Comparative oncology, the evaluation of novel cancer therapies in animals with spontaneous cancer, can be utilized to inform and accelerate clinical translation. Preclinical murine studies demonstrate that single shot systemic therapy with a VSV-IFNβ-NIS, a novel recombinant oncolytic Vesicular stomatitis virus (VSV), can induce curative remission in tumor bearing mice. Clinical translation of VSV-IFNβ-NIS therapy is dependent on comprehensive assessment of clinical toxicities, virus shedding, pharmacokinetics, and efficacy in clinically relevant models...
November 20, 2017: Molecular Cancer Therapeutics
https://www.readbyqxmd.com/read/29158064/mirna-223-functions-as-both-prognostic-biomarker-and-tumor-suppressor-in-mantle-cell-lymphoma-through-targeting-sox11
#18
REVIEW
Keshu Zhou, Xiaoyan Feng, Yanying Wang, Yanyan Liu, Long Tian, Wenli Zuo, Shuhua Yi, Xudong Wei, Yongping Song, Lugui Qiu
Mantle cell lymphoma (MCL) is an aggressive lymphoid malignance characterized by cytogenetic aberration of t(11;14), although it is not the prerequisite. Until now, the pathogenesis of MCL remains not fully interpreted. Our current study showed that miR-223 was down-regulated in purified CD19+ lymphocytes from MCL patients (n=21) compared with that of normal donors (n=20). In addition, patients with high-risk mantle international prognostic index, elevated LDH, performance status>2 were more likely to have much lower miR-223 expression...
November 17, 2017: Experimental Hematology
https://www.readbyqxmd.com/read/29157092/single-agent-and-synergistic-combinatorial-efficacy-of-first-in-class-small-molecule-imipridone-onc201-in-hematological-malignancies
#19
Varun V Prabhu, Mala K Talekar, Amriti R Lulla, C Leah B Kline, Lanlan Zhou, Junior Hall, A Pieter J Van den Heuvel, David T Dicker, Jawad Babar, Stephan A Grupp, Mathew J Garnett, Ultan McDermott, Cyril H Benes, Jeffrey J Pu, David F Claxton, Nadia Khan, Wolfgang Oster, Joshua E Allen, Wafik S El-Deiry
ONC201, founding member of the imipridone class of small molecules, is currently being evaluated in advancer cancer clinical trials. We explored single agent and combinatorial efficacy of ONC201 in preclinical models of hematological malignancies. ONC201 demonstrated (GI50 1-8 µM) dose- and time-dependent efficacy in acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic myelogenous leukemia (CML), chronic lymphocytic leukemia (CLL), diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), Burkitt's lymphoma, anaplastic large cell lymphoma (ALCL), cutaneous T-cell lymphoma (CTCL), Hodgkin's lymphoma (nodular sclerosis) and multiple myeloma (MM) cell lines including cells resistant to standard of care (dexamethasone in MM) and primary samples...
November 20, 2017: Cell Cycle
https://www.readbyqxmd.com/read/29153898/the-significance-of-the-pd-l1-expression-in-non-small-cell-lung-cancer-trenchant-double-swords-as-predictive-and-prognostic-markers
#20
REVIEW
Kazuki Takada, Gouji Toyokawa, Fumihiro Shoji, Tatsuro Okamoto, Yoshihiko Maehara
Lung cancer is the leading cause of death due to cancer worldwide. Surgery, chemotherapy, and radiotherapy have been the standard treatment for lung cancer, and targeted molecular therapy has greatly improved the clinical course of patients with non-small-cell lung cancer (NSCLC) harboring driver mutations, such as in epidermal growth factor receptor and anaplastic lymphoma kinase genes. Despite advances in such therapies, the prognosis of patients with NSCLC without driver oncogene mutations remains poor. Immunotherapy targeting programmed cell death-1 (PD-1) and programmed cell death-ligand 1 (PD-L1) has recently been shown to improve the survival in advanced NSCLC...
October 28, 2017: Clinical Lung Cancer
keyword
keyword
7294
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"